Abstract: Radiolabeled somatostatin subtype 2 receptor (SST2R)-antagonists have shown advantageous profiles for cancer theranostics compared with agonists. On the other hand, the newly introduced hybrid chelator (6-pentanoic acid)-(6-amino)methyl-1,4-diazepintriacetate (DATA5m) rapidly binds Ga-68 (t1/2: 67.7 min) at much lower temperature, thus allowing for quick access to “ready-for-injection” [68Ga]Ga-tracers in hospitals. We herein introduce [68Ga]Ga-DATA5m-LM4 for PET/CT imaging of SST2R-positive human tumors. LM4 was obtained by 4Pal3/Tyr3-substitution in the known SST2R antagonist LM3 (H-DPhe-c[DCys-Tyr-DAphe(Cbm)-Lys-Thr-Cys]-DTyr-NH2) and DATA5m was coupled at the N-terminus for labeling with radiogallium (Ga-67/68). [68Ga]Ga-DATA5m-LM4 was evaluated in HEK293-SST2R cells and mice models in a head-to-head comparison with [67Ga]Ga-DOTA-LM3. Clinical grade [68Ga]Ga-DATA5m-LM4 was prepared and injected in a neuroendocrine tumor (NET) patient for PET/CT imaging. DATA5m-LM4 displayed high SST2R binding affinity. [67Ga]Ga-DATA5m-LM4 showed markedly higher uptake in HEK293-SST2R cells versus [68Ga]Ga-DOTA-LM3 and was stable in vivo. In HEK293-SST2R xenograft-bearing mice, it achieved longer tumor retention and less kidney uptake than [67Ga]Ga-DOTA-LM3. [68Ga]Ga-DATA5m-LM4 accurately visualized tumor lesions with high contrast on PET/CT. In short, [68Ga]Ga-DATA5m-LM4 has shown excellent prospects for the PET/CT diagnosis of SST2R-positive tumors, further highlighting the benefits of Ga-68 labeling in a hospital environment via the DATA5m–chelator route.

Keywords: somatostatin receptor antagonist; hybrid chelator; Ga-68 labeling; Ga-67 labeling; PET-radiotracer; PET diagnostic imaging

1. Introduction

The advent of radiolabeled somatostatin analogs targeting the somatostatin subtype 2 receptor (SST2R), one frequently and highly expressed in neuroendocrine tumors (NETs), has revolutionized the management of NET patients [1–3]. Accordingly, diagnosis and staging of NETs with positron emission (PET) or single photon emission computed tomography (SPECT) using somatostatin analogs has enabled a selection of patients eligible for subsequent therapy with particle emitters to eradicate SST2R-positive tumor lesions. Furthermore, PET or SPECT imaging has been instrumental in addressing important therapy-related questions on dosimetry, therapy planning and post-treatment assessment of therapeutic efficacy. Clearly, such an intertwined diagnosis and therapy, “theranostic”, approach excellently harmonizes with modern precision medicine principles [4,5]. Until recently, octapeptide analogs of native somatostatin-14 (SS-14), such as Tyr3-octreotate (TATE, H-DPhe-c[Cys-Tyr-DTrp-Lys-Thr-Cys]-Thr-OH) and Tyr3-octreotide (TOC, H-DPhe-c[Cys-Tyr-DTrp-Lys-Thr-Cys]-Thr(OH)), have been properly modified to accommodate radiometals of clinical interest for diagnosis (SPECT—Tc-99m, In-111; PET: Ga-68, Cu-64) [6–9] and therapy (Lu-177, Ac-225, Pb-212) [10–12]. The theranostic pair [68Ga]Ga/[177Lu]Lu-DOTA-TATE (DOTA, 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid) represents a

...
successful paradigm of this approach, having been approved by the United States Food and Drug Agency (FDA) and the European Medicines Agency (EMA) for treatment of human SST2R-positive tumors [3,13].

The above class of octreotide-derived radioligands has shown agonistic properties at the SST2R, associated with fast internalization in target cells after binding to the cell membrane receptor. In fact, high radioligand uptake and retention in tumor lesions have been directly linked to fast internalization in cancer cells [7,8]. In the course of these developments, though radiolabeled octapeptides with antagonistic properties at the SST2R, it turned out to perform better than agonists [14–19]. Despite their lack of internalization, radiolabeled SST2R-antagonists displayed higher and more persistent uptake in tumor-bearing mice combined with faster background clearance. Such properties were next translated in NET patients, challenging the initial reading of SST2R-agonism as a major element of the success for somatostatin radioligands. Studies at the molecular and cellular level revealed that radiolabeled SST2R-antagonists bind to both active and inactive conformations of the receptor. Hence, antagonists have a far higher number of binding sites at their disposal than agonists, binding to the sub-population of active SST2Rs only [20]. A fair number of SST2R-antagonists have been developed in recent years carrying suitable chelators for labeling with radiometals of interest [21,22]. Such an example is DOTA-LM3 (DOTA-DPhe-c[DCys-Tyr-DAph(Cbm)-Lys-Thr-Cys]-DTyr-NH2; DAph(Cbm), D-4-(carbamoyl)amino-phenylalanine) (Figure 1). DOTA-LM3 labeled with Ga-68 and other radiometals has shown promising qualities during preclinical and clinical studies for use in NET theranostics [21,22].

![Chemical structures of (a) DOTA-LM3; (b) DATA5m-LM4; the two analogs differ in the chelator and in the residue at position 3: Tyr (in LM3) and (4-pyridyl)alanine (4Pal, in LM4).](image)

It should be noted however that incorporation of Ga-68 to DOTA requires heating, complicating hospital logistics in view of the short half-life of Ga-68 (t1/2: 67.7 min) [23,24]. An elegant way to tackle this problem is provided by the hybrid chelator (6-pentanoic acid)-6-(amino)methyl-1,4-diazepinetracacetate (DATA5m). DATA5m rapidly coordinates Ga-68 at much lower temperature, thus allowing for quick and convenient access to “ready-for-injection” [68Ga]Ga-tracers in hospitals [25–30]. We herein present [68Ga]Ga-DATA5m-LM4, as a new candidate for PET/CT imaging of SST2R-positive tumors. LM4 is a 4Pal3/Tyr3-analog of LM3 [21,22,31,32] (4Pal3, 3-(4-pyridyl)alanine), which was coupled to DATA5m (Figure 1). In the present work, DOTA-LM3 and DATA5m-LM4 were labeled with the longer-lived Ga-67 (t1/2: 78.3 h) surrogate for convenient and direct comparison of their preclinical profiles in HEK293-SST2R cells and HEK293-SST2R tumor-bearing mice. Moreover, clinical grade [68Ga]Ga-DATA5m-LM4 was easily produced in a hospital setting and evaluated in a NET patient applying PET/CT in a “proof-of-principle” approach.
2. Results

2.1. Ligands and Radioligands

Labeling of the new DATA\textsuperscript{5m}-LM4 analog with Ga-67 was accomplished within 15 min at room temperature affording the [\textsuperscript{67}Ga]Ga-DATA\textsuperscript{5m}-LM4 in high radiochemical purity (RCP \(> 96\%\)) at a molar activity of 3.7 MBq/nmol, as verified by radioanalytical HPLC methods (Supplementary Materials Figure S1). Similar results could be obtained with the DOTA-derivatized analogs DOTA-TOC and DOTA-LM3 only by heating of the labeling reaction mixture for 30 min at 90 °C. Radioligands were used as such in all further experiments without purification; the respective solutions were tested before and after all in vitro assays and animal studies (analytical data for DATA\textsuperscript{5m}-LM4 and DOTA-LM3 in Table S1, Supplementary Materials).

Labeling of DATA\textsuperscript{5m}-LM4 with Ga-68 for clinical use was conducted by an automatic system. Reaction at 50 °C provided RCP \(\geq 98\%\). The automated synthesis led to activities between 413 MBq and 596 MBq for 50 µg of DATA\textsuperscript{5m}-LM4 (corresponding to 12.5–18 MBq/nmol molar activity; Supplementary Materials Figure S3).

2.2. In Vitro Studies

2.2.1. Binding Affinities for the Human SST\textsubscript{2}R

The binding affinities of DATA\textsuperscript{5m}-LM4 and [\textsuperscript{nat}Ga]Ga-DATA\textsuperscript{5m}-LM4 for the human SST\textsubscript{2}R were determined via competition binding assays against [\textsuperscript{125}I-Tyr\textsuperscript{25}]LT-TSS28 in freshly harvested HEK293-SST\textsubscript{2}R cell membranes [28,30,33]. As depicted in Figure 2, DATA\textsuperscript{5m}-LM4 as well as its [\textsuperscript{nat}Ga]Ga-tagged version displaced [\textsuperscript{125}I-Tyr\textsuperscript{25}]LT-TSS28 from SST\textsubscript{2}R-binding sites in the membrane homogenates in a monophasic and dose-dependent manner. Their affinities for the SST\textsubscript{2}R were comparable, with IC\textsubscript{50} values (mean \(\pm\) standard deviation (sd), \(n = 3\)) of 1.24 \(\pm\) 0.20 nM for DATA\textsuperscript{5m}-LM4 and 1.61 \(\pm\) 0.32 nM for [\textsuperscript{nat}Ga]Ga-DATA\textsuperscript{5m}-LM4 (\(p > 0.05\)).

![Figure 2](image)

**Figure 2.** Displacement of [\textsuperscript{125}I-Tyr\textsuperscript{25}]LT-TSS28 from SST\textsubscript{2}R binding sites in HEK293-SST\textsubscript{2}R cell membrane homogenates by increasing concentrations of: \(\Box\) DATA\textsuperscript{5m}-LM4 (IC\textsubscript{50} = 1.24 \(\pm\) 0.20 nM, \(n = 3\)); \(\textbullet\) [\textsuperscript{nat}Ga]Ga-DATA\textsuperscript{5m}-LM4 (IC\textsubscript{50} = 1.61 \(\pm\) 0.32 nM, \(n = 3\)); results represent the average IC\textsubscript{50} values \pm sd, \(n\) is the number of independent experiments performed in triplicate.

2.2.2. Uptake/Internalization in HEK293-SST\textsubscript{2}R Cells

Comparative uptake and internalization of [\textsuperscript{67}Ga]Ga-DOTA-TOC, [\textsuperscript{67}Ga]Ga-DOTA-LM3 and [\textsuperscript{67}Ga]Ga-DATA\textsuperscript{5m}-LM4 in HEK293-SST\textsubscript{2}R after 1 h at 37 °C are summarized in Table S1. We observe that [\textsuperscript{67}Ga]Ga-DATA\textsuperscript{5m}-LM4 is taken up by the cells most efficiently (28.86 \(\pm\) 1.69%), followed by [\textsuperscript{67}Ga]Ga-DOTA-TOC (20.98 \(\pm\) 0.71%; \(p < 0.0001\)) and [\textsuperscript{67}Ga]Ga-DOTA-LM3, which achieved very low cell uptake (2.51 \(\pm\) 0.36%; \(p < 0.0001\)) within this group of radioligands. Notably, the bulk of radioactivity was found in the cell membrane in the case of [\textsuperscript{67}Ga]Ga-DATA\textsuperscript{5m}-LM4 (25.39 \(\pm\) 1.48% membrane-bound fragment), whereas for [\textsuperscript{67}Ga]Ga-DOTA-TOC, it already internalized within the cells (19.57 \(\pm\) 0.64% internalized fragment). This distinct cell distribution pattern between [\textsuperscript{67}Ga]Ga-DATA\textsuperscript{5m}-LM4 and [\textsuperscript{67}Ga]Ga-DOTA-TOC is consistent with an SST\textsubscript{2}R antagonist and agonist behavior.
Thus, for [67Ga]Ga-DATA5m-LM4 the lower renal uptake and [67Ga]Ga-DOTA-LM3 unfavorably declined within the same time period (25.31 ± 6.23%IA/g and 16.83 ± 1.22%IA/g, respectively [14,16]. In all cases, cell uptake was banned in the presence of excess TATE, revealing an SST2R-mediated process.

![Graph](image)

**Figure 3.** Uptake/internalization of [67Ga]Ga-DOTA-TOC, [67Ga]Ga-DOTA-LM3 and [67Ga]Ga-DATA5m-LM4 after 1 h incubation in HEK293-SST2R cells at 37 °C; results represent the average values ± sd, acquired from 3 independent experiments performed in triplicate; MB: membrane bound, total uptake: MB + internalized, NS MB: non-specific membrane bound and NS Intern: non-specific internalized; non-specific values were determined in the presence of 1 µM TATE.

2.3. Animal Studies

2.3.1. In Vivo Metabolic Stability of [67Ga]Ga-DATA5m-LM4

The in vivo formation of radio metabolites following injection of [67Ga]Ga-DATA5m-LM4 in healthy mice could be ruled out by radio-HPLC analysis of blood samples collected 5 min post-injection (pi) [34], revealing the high metabolic stability of the octapeptide radiotracer (Supplementary Materials Figure S2).

2.3.2. Comparison of [67Ga]Ga-DATA5m-LM4 vs. [67Ga]Ga-DOTA-LM3 in Tumor-Bearing Mice

The biodistribution patterns of [67Ga]Ga-DATA5m-LM4 vs. [67Ga]Ga-DOTA-LM3 were compared at 1 and 4 h pi in male SCID mice bearing twin HEK293-SST2R and wild type (wt)HEK293 tumors in their flanks. Results were calculated as percentage of the injected activity per gram tissue (%IA/g) and represent average values ± sd (n = 4); data are shown in Figure 4 (and in numerical values in Table S2, Supplementary Materials).

![Graph](image)

**Figure 4.** Comparative biodistribution of [67Ga]Ga-DOTA-LM3 and [67Ga]Ga-DATA5m-LM4 in SCID mice bearing twin HEK293-SST2R and wtHEK293 xenografts, at 1 h (solid bars) and 4 h (chequered bars) pi. Results are expressed as %IA/g and represent the average values ± sd, n = 4; Bl: blood, Li: liver, He: heart, Ki: kidneys, St: stomach, In: intestines, Sp: spleen, Mu: muscle, Lu: lungs, Pa: pancreas, Fe: femur, Tu+: HEK293-SST2R tumor, Tu-: wtHEK293 tumor.

Both compounds displayed high uptake in the HEK293-SST2R tumors at all time intervals and minimal uptake in the wtHEK293 tumors, which were devoid of SST2R expression.
(p < 0.0001), in line with a receptor-mediated process. For example, the uptake [$^{67}$Ga]Ga-DATA$^{5m}$-LM4 amounted to $20.76 \pm 6.19\%$IA/g in the HEK293-SST$_2$R vs. $2.10 \pm 0.43\%$IA/g in the wtHEK293-SST$_2$R xenografts at 1 h pi (p < 0.0001). The respective values for [$^{65}$Ga]Ga-DOTA-LM3 were $25.31 \pm 6.23\%$IA/g and $1.45 \pm 0.27\%$IA/g (p < 0.0001). Interestingly, the uptake of [$^{67}$Ga]Ga-DATA$^{5m}$-LM4 in the SST$_2$R xenografts remained in the same level between 1 and 4 h pi ($20.76 \pm 6.19\%$IA/g and $23.70 \pm 2.82\%$IA/g, respectively; p > 0.05).

In contrast, tumor uptake of [$^{67}$Ga]Ga-DOTA-LM3 unfavorably declined within the same time period ($25.31 \pm 6.23\%$IA/g and $16.83 \pm 1.22\%$IA/g, respectively; p < 0.0001).

The radioligands displayed fast background clearance predominantly via the kidneys and the urinary tract. Interestingly, [$^{67}$Ga]Ga-DATA$^{5m}$-LM4 showed higher uptake in a number of SST$_2$R-positive mice tissues at 1 h pi compared with [$^{65}$Ga]Ga-DOTA-LM3, such as the pancreas ($22.96 \pm 4.06\%$IA/g vs. $1.49 \pm 0.71\%$IA/g for [$^{65}$Ga]Ga-DOTA-LM3; p < 0.0001) and the stomach ($6.16 \pm 3.00\%$IA/g vs. $0.80 \pm 0.17\%$IA/g for [$^{65}$Ga]Ga-DOTA-LM3; p < 0.001). These discrepancies however drastically diminished at 4 h pi. A further striking difference in the biodistribution of the two analogs was observed in their kidney uptake and retention. Thus, for [$^{67}$Ga]Ga-DATA$^{5m}$-LM4 the lower renal uptake within this time frame ($35.95 \pm 5.96\%$IA/g to $37.65 \pm 3.44\%$IA/g, p < 0.0001)) 

The radioligands displayed fast background clearance predominantly via the kidneys and the urinary tract. Interestingly, [$^{67}$Ga]Ga-DATA$^{5m}$-LM4 showed higher uptake in a number of SST$_2$R-positive mice tissues at 1 h pi compared with [$^{65}$Ga]Ga-DOTA-LM3, such as the pancreas ($22.96 \pm 4.06\%$IA/g vs. $1.49 \pm 0.71\%$IA/g for [$^{65}$Ga]Ga-DOTA-LM3; p < 0.0001) and the stomach ($6.16 \pm 3.00\%$IA/g vs. $0.80 \pm 0.17\%$IA/g for [$^{65}$Ga]Ga-DOTA-LM3; p < 0.001). These discrepancies however drastically diminished at 4 h pi. A further striking difference in the biodistribution of the two analogs was observed in their kidney uptake and retention. Thus, for [$^{67}$Ga]Ga-DATA$^{5m}$-LM4 the lower renal uptake within this time frame ($35.95 \pm 5.96\%$IA/g to $37.65 \pm 3.44\%$IA/g, p < 0.0001))

Thus, for [$^{67}$Ga]Ga-DATA$^{5m}$-LM4 the lower renal uptake declined between 1 and 4 h pi ($19.94\%$IA/g to $13.72\%$IA/g, p < 0.0001). The respective values for [$^{67}$Ga]Ga-DATA$^{5m}$-LM4 in the HEK293-SST$_2$R xenografts remained in the same level between 1 and 4 h pi ($20.76\%$IA/g and $23.70\%$IA/g, respectively; p > 0.05).

In contrast, tumor uptake of [$^{67}$Ga]Ga-DOTA-LM3 unfavorably declined within the same time period ($25.31\%$IA/g and $16.83\%$IA/g, respectively; p < 0.0001).

The radioligands displayed fast background clearance predominantly via the kidneys and the urinary tract. Interestingly, [$^{67}$Ga]Ga-DATA$^{5m}$-LM4 showed higher uptake in a number of SST$_2$R-positive mice tissues at 1 h pi compared with [$^{65}$Ga]Ga-DOTA-LM3, such as the pancreas ($22.96\%$IA/g vs. $1.49\%$IA/g for [$^{65}$Ga]Ga-DOTA-LM3; p < 0.0001) and the stomach ($6.16\%$IA/g vs. $0.80\%$IA/g for [$^{65}$Ga]Ga-DOTA-LM3; p < 0.001). These discrepancies however drastically diminished at 4 h pi. A further striking difference in the biodistribution of the two analogs was observed in their kidney uptake and retention. Thus, for [$^{67}$Ga]Ga-DATA$^{5m}$-LM4 the lower renal uptake declined between 1 and 4 h pi ($19.94\%$IA/g to $13.72\%$IA/g, p < 0.0001) as opposed to [$^{67}$Ga]Ga-DOTA-LM3, which was strongly retained in the kidneys within this time frame ($35.95\%$IA/g to $37.65\%$IA/g, p > 0.05), with a more attractive pharmacokinetic profile assigned to the new radiotracer.

### 2.4. PET/CT of a NET Patient

A 60-year old patient with well-differentiated, functioning NET of the pancreas with extensive hepatic and peritoneal metastases, a Ki-67 index of 52% G3, and was MSI positive, was imaged in November 2021 with [$^{68}$Ga]Ga-DATA$^{5m}$-LM4. He was previously treated with Whipple operation, CAPTEM chemotherapy, segmental liver resection, transarterial chemoembolization of metastases in the right liver lobe, Sunitinib, Everolimus, Pembrolizumab, Temodal and Sandostatin. The patient had received a total of 6 cycles of PRRT, cumulated administered radioactivity of 44 GBq Lu-177. At restaging in November 2021 with [$^{68}$Ga]Ga-DATA$^{5m}$-LM4 PET/CT (Figure 5b) and prior to his 5th and 6th cycle, the patient showed progressive disease consistent with massive progression of liver metastases, not seen on [$^{64}$Cu]Cu-DOTA-TATE PET/CT in April 2021 (Figure 5a).

![Figure 5. MIPs and transversal images of a patient with pancreatic NET, presenting hepatic and peritoneal lesions 1 h after intravenous injection of the radioligand. (a) [$^{64}$Cu]Cu-DOTA-TATE PET/CT, (b) [$^{68}$Ga]Ga-DATA$^{5m}$-LM4 PET/CT of the patient having received several treatments including several cycles of PRRT with [$^{177}$Lu]Lu-DOTA-TATE, but remaining with progressive disease.](image-url)
3. Discussion

We herein introduce \[^{68}\text{Ga}]\text{Ga-DATA}^{5m}\text{-LM4}\), as an SST\(_2\)R antagonist in the diagnosis of NETs with PET/CT. The new tracer is based on the known SST\(_2\)R antagonist LM3 [21,22] following 4Pal\(_3\)/Tyr\(_3\)-substitution [32] in the cyclic octapeptide chain. Notably, DATA\(^{5m}\text{-LM4}\) can be labeled with Ga-67/68 at much lower temperatures than other DOTA-derivatized peptides (including DOTA-LM3) by virtue of the hybrid DATA\(^{5m}\) chelator attached on its N-terminus (Figure 1) [25–30]. For convenient completion of the preclinical study, DATA\(^{5m}\text{-LM4}\), DOTA-LM3 and the SST\(_2\)R-agonist reference DOTA-TOC were labeled with the longer-lived Ga-67 (t\(_{1/2}\): 78.3 h) as a Ga-68 surrogate (t\(_{1/2}\): 67.7 min).

Unlike the above two DOTA-conjugates requiring heating at 90 °C for 30 min during labeling, DATA\(^{5m}\text{-LM4}\) was successfully labeled by a mere 15 min incubation at room temperature. The quality control of radiolabeled products adopting radioanalytical HPLC methods confirmed in all cases a >98% RCP at a molar activity of 3.7 MBq/nmol. Therefore, all radioligands were further used without purification in all preclinical experiments that followed.

During competition binding assays against \[^{125}\text{I}]\text{I-LTT-SS28}\) on HEK293-SST\(_2\)R cell-membranes [30], DATA\(^{5m}\text{-LM4}\) and its Ga-tagged version \[^{68}\text{Ga}]\text{Ga-DATA}^{5m}\text{-LM4}\) showed high receptor affinity, reflected in the single-digit nanomolar IC\(_{50}\) values (1.24 ± 0.20 nM and 1.61 ± 0.32 nM, respectively; Figure 2). It is interesting to note that the IC\(_{50}\) values reported for DOTA-LM3 and \[^{68}\text{Ga}]\text{Ga-DOTA-LM3}\) during SST\(_2\)R autoradiography against the same radioligand were 1.4 ± 0.5 nM and 12.5 ± 4.3 nM, respectively [15,22]. On the other hand, by changing the metal to Lu the IC\(_{50}\) determined for \[^{125}\text{Lu}]\text{Lu-DOTA-LM3}\) was 1.61 ± 0.32 nM and by replacing DOTA by NODAGA, the IC\(_{50}\) value for \[^{68}\text{Ga}]\text{Ga-NODAGA-LM3}\) reached 1.3 ± 0.3 nM [21,22]. These results reveal the strong impact of the metal chelate on SST\(_2\)R affinity. Thus, Ga-labeling of DOTA-LM3 leads to a loss of receptor binding affinity compared with unlabeled DOTA-LM3 by one order of magnitude. In turn, these data reveal that the binding affinity of Ga-labeled DATA\(^{5m}\text{-LM4}\) is 10-fold better than that of Ga-labeled DOTA-LM3, while both unlabeled compounds show similar binding affinity. Specific uptake of the \[^{68}\text{Ga}]\text{Ga-DATA}^{5m}-\text{LM4}\) in HEK293-SST\(_2\)R cells followed this affinity pattern (Figure 3), with \[^{68}\text{Ga}]\text{Ga-DATA}^{5m}\text{-LM4}\) taken up much more successfully by the cells at 1 h incubation compared with \[^{68}\text{Ga}]\text{Ga-DOTA-LM3}\) (28.86 ± 1.69 % vs. 2.51 ± 0.36%, respectively). It is also interesting to compare the cell distribution pattern of radioactivity between \[^{68}\text{Ga}]\text{Ga-DATA}^{5m}\text{-LM4}\) with the radioactivity predominantly found on the cell membrane and \[^{68}\text{Ga}]\text{Ga-DOTA-TOC}\) with the bulk of radioactivity internalized. These two distinct patterns correspond to a non-internalizing receptor antagonist and an internalizing agonist profile.

The biodistribution of \[^{68}\text{Ga}]\text{Ga-DATA}^{5m}\text{-LM4}\) and \[^{68}\text{Ga}]\text{Ga-DOTA-LM3}\) were directly compared in male SCID mice bearing twin HEK293-SST\(_2\)R and wtHEK293 xenografts in their flanks, with the latter serving as negative controls being devoid of SST\(_2\)R expression. The new tracer \[^{68}\text{Ga}]\text{Ga-DATA}^{5m}\text{-LM4}\) showed a favorably constant uptake in the implanted HEK293-SST\(_2\)R tumors in the period between 1 and 4 h pi, as opposed to \[^{68}\text{Ga}]\text{Ga-DOTA-LM3}\) declining from the tumor within this interval. Another interesting advantage of \[^{68}\text{Ga}]\text{Ga-DATA}^{5m}\text{-LM4}\) is the significantly lower kidney uptake at 1 h pi, which further decreased at 4 h pi. In contrast, \[^{68}\text{Ga}]\text{Ga-DOTA-LM3}\) retained a much higher kidney uptake within this time frame (Figure 4; Table S2, Supplementary Materials). It is interesting to note that biodistribution results on \[^{68}\text{Ga}]\text{Ga-DOTA-LM3}\) at 1 h pi are well comparable with those previously reported for \[^{68}\text{Ga}]\text{Ga-DOTA-LM3}\) on a similar HEK293-SST\(_2\)R tumor model in female nude mice; the same total peptide amount (10 pmol) was injected in both cases [22]. Summarizing the above observations, \[^{68}\text{Ga}]\text{Ga-DATA}^{5m}\text{-LM4}\) displayed i. lower renal uptake than \[^{68}\text{Ga}]\text{Ga-DOTA-LM3}\) at all time points, ii. stable tumor uptake vs. the decreasing tumor uptake of \[^{68}\text{Ga}]\text{Ga-DOTA-LM3}\), resulted in an overall better profile. Thus, tumor-to-kidney ratios increased over time for \[^{68}\text{Ga}]\text{Ga-DATA}^{5m}\text{-LM4}\) (1.04 at 1 h up to 1.73 at 4 h pi), as opposed to \[^{68}\text{Ga}]\text{Ga-DOTA-LM3}\) showing decreasing tumor-to-kidney ratios within this time frame (0.70 at 1 h down to 0.45 at 4 h pi).
The above discussed promising preclinical results prompted us to test clinical grade \([^{68}\text{Ga}]\text{Ga-DATA}^{5m}\)-LM4 in a NET patient in a preliminary “proof-of-principal” experiment. It should be noted that routine labeling with Ga-68 was successful and reproducible via an automated module in the hospital and mild heating at 50 °C in an overall production time of 15 min. Notably, tumor lesions were accurately visualized in the patient with a high contrast on PET/CT (Figure 5).

The present study has revealed attractive features for \([^{68}\text{Ga}]\text{Ga-DATA}^{5m}\)-LM4 firstly at the preclinical level, such as high receptor affinity and cell uptake, in vivo robustness as well as high and sustained uptake in SST2R-positive tumors in mice combined with a favorable washout from the kidneys into the urine. These excellent qualities were replicated in a NET patient injected with clinical grade of \([^{68}\text{Ga}]\text{Ga-DATA}^{5m}\)-LM4 applying PET/CT. Labeling of the new agent was fast, simple and reproducible for both preclinical and clinical preparations via the DATA\(^{5m}\)-chelator route. Further systematic clinical studies are warranted to establish the diagnostic value of \([^{68}\text{Ga}]\text{Ga-DATA}^{5m}\)-LM4 in the detection of NETs with PET/CT.

4. Materials and Methods

4.1. Chemicals, Ligands and Radionuclides

Common chemicals used were reagent grade except for HPLC solvents which were HPLC grade. DOTA-TOC (TOC, [Tyr\(^3\)]octreotide: DPhe-c[Cys-Tyr-DTrp-Lys-Thr-Cys]-Thr-ol; DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) was purchased from ABX Advanced Biochemical Compounds, GmbH (Radeberg, Germany). DOTA-LM3 (LM3: p-Cl-Phe-c[DCys-Tyr-D-4-(carbamoyl)amino-Phe-Lys-Thr-Cys]-DTyr-NH\(_2\)) was provided by PiChem Forschungs- und Entwicklungs GmbH (Raaba-Grambach, Austria) and DATA\(^{5m}\)-LM4 (LM4: p-Cl-Phe-c[DCys(4-pyridyl)Ala-D-4-(carbamoyl)amino-Phe-Lys-Thr-Cys]-DTyr-NH\(_2\)); DATA\(^{5m}\): (6-pentanoic acid)-6-(amino)ethyl-1,4-diazepinetriacetate) was obtained from Peptide Specialty Laboratories GmbH (Heidelberg Germany); analytical data of the two conjugates, comprising MALDI-TOF mass spectroscopy results and purity determined by HPLC analysis is compiled in Table S1 (Supplementary File). TATE (H-DPhe-c[Cys-Tyr-DTrp-Lys-Thr-Cys]-Thr-OH) was synthesized on the solid support, as previously described [28]. LTT-SS28 (H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Leu-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-c[Cys-Lys-Asn-Phe-Phe-DTrp-Lys-Thr-Tyr-Ser-Cys]-OH) was obtained from Bachem AG (Bubbendorf, Switzerland). \([^{68}\text{Ga}]\text{Ga(NO}_3\text{)}_3\) was purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA).

Gallium-67 in the form of a \([^{67}\text{Ga}]\text{GaCl}_3\) solution in dilute HCl was provided by IDB Holland BV (Baarle-Nassau, The Netherlands) and used as a surrogate of Ga-68 in preclinical studies. For the clinical preparation, Ga-68 from a pharmaceutical grade commercial \([^{68}\text{Ge}]\text{Ge/}[^{68}\text{Ga}]\text{Ga-generator (GalliaPharm}}\) from Eckert & Ziegler Strahlen- und Medizintechnik AG, Berlin, Germany) was employed. For the preparation of \([^{125}\text{I}]\text{Tyr}^{25}\) LTT-SS28, \([^{125}\text{I}]\text{NaI was provided by PerkinElmer (Waltham, MA, USA in dilute sodium hydroxide solution (pH 8–11).}

4.1.1. Radiolabeling

Lyophilized peptide conjugates were dissolved in HPLC-grade H\(_2\)O and distributed in 50 µL aliquots in Eppendorf Protein LoBind tubes. These were stored at −20 °C. For labeling with Ga-67, each conjugate (5 nmol) was mixed with 17–20 MBq of \([^{67}\text{Ga}]\text{GaCl}_3\) and 1 M sodium acetate was added to adjust the pH of the reaction to 4.0. The mixture was incubated at room temperature for 15 min for \([^{67}\text{Ga}]\text{Ga-DATA}^{5m}\)-LM4 and at 90 °C for 30 min for \([^{67}\text{Ga}]\text{Ga-DOTA-TOC and}[^{67}\text{Ga}]\text{Ga-DOTA-LM3. Sodium EDTA (0.1 M, pH 4.0) was added to a final concentration of 1 mM as a scavenger of “free”}[^{68}\text{Ga}]\text{Ga}^{3+}\) traces [28].

Clinical grade \([^{68}\text{Ga}]\text{Ga-DATA}^{5m}\)-LM4 was obtained via an automatic mini all-in-one cassette-based module from Trasis (Ans, Belgium). Labeling with Ga-68 proceeded at 50 °C in sodium acetate buffer (0.7 M, pH 5.5, 1 mL) resulting in a >98 RCP within 10 min reaction time [27,29]. The automated synthesis yielded activities between 413 MBq and 596 MBq.
(avg. 508 ± 86 MBq; n = 9) after 15 min of production with 50 µg DATA<sup>5m</sup>-LM4 and 20 min of quality control.

The [<sup>125</sup>I][Tyr<sup>25</sup>]LTT-SS28 was obtained from LTT-SS28 according to the chloramine-T method using [<sup>125</sup>I]NaI in a 0.1 M NaOH solution for the radioiodination [30]. The radioligand was isolated in a pure form by HPLC and aliquots thereof in 0.1% BSA-PBS buffer were kept at −20°C; these were used for competition binding experiments (molar activity of 74 GBq/µmol). For the preparation of [<sup>nat</sup>Ga]<sup>67</sup>Ga-DATA<sup>5m</sup>-LM4, stock solution of DATA<sup>5m</sup>-LM4 (60 µL, 2 mM, 120 nmol) was placed in an Eppendorf Protein LoBind<sup>®</sup> centrifuge tube and a [<sup>nat</sup>Ga]<sup>67</sup>Ga(NO<sub>3</sub>)<sub>3</sub> solution in 1 M sodium acetate buffer (pH 4.0) was added. The mixture was heated at 75°C for 1 h and analysis was conducted applying reversed-phase high performance liquid chromatography (RP-HPLC).

### 4.1.2. Radiochemical Analysis

Analyses were performed on a Waters Chromatograph based on a 600E multi-solvent delivery system applying twin detection modes: (a) for photometric detection, a Waters 2998 photodiode array detector (Waters, Vienna, Austria) was used (DATA<sup>5m</sup>-LM4 and [<sup>nat</sup>Ga]<sup>67</sup>Ga-DATA<sup>5m</sup>-LM4), (b) for radiometric detection, a Gabi gamma-detector (Raytest, RSM Analytische Instrumente GmbH, Straubenhardt, Germany) was applied (detection of radioligands). The system was monitored and data was processed by the Empower Software (Waters, Milford, MA, USA). For radiochemical analyses, samples were eluted through a Xterra RP18 cartridge column (5 µm, 3.9 mm × 20 mm, Waters, Eschborn, Germany), applying the following linear gradient: 100%A/0% B to 60%A/40% B in 40 min, whereby A = 0.1% TFA in H<sub>2</sub>O (v/v) and B = MeCN (system 1). Radioligands were used without further purification in all subsequent experiments and suitable samples were tested before and after the end of all biological experiments. Retention times (t<sub>R</sub>) were as follows: [<sup>67</sup>Ga]<sup>67</sup>Ga-DATA<sup>5m</sup>-LM4: 22.5 min, [<sup>67</sup>Ga]<sup>67</sup>Ga-DOTA-TOC: 21.4 min and [<sup>67</sup>Ga]<sup>67</sup>Ga-DOTA-LM3: 24.7 min.

The handling of solutions containing beta-/gamma-emitting radionuclides was conducted by authorized personnel in compliance with European radiation safety guidelines. Licensed facilities were supervised by the Greek Atomic Energy Commission (GAEC, license #A/435/17092/2019 and #A/435/15767/2019).

For quality control of clinical grade [<sup>68</sup>Ga]<sup>68</sup>Ga-DATA<sup>5m</sup>-LM4, radio-TLC was applied (TLC silica gel 60 F<sub>254</sub> Merck) whereby the plates were developed with (1) 0.1 M citrate buffer pH 4 and (2) a 1:1 mixture of 1 M ammonium acetate and MeOH (v:v) as the mobile phase. TLC plates were measured on a miniGita TLC scanner from Elysia-Raytest (Angleur, Belgium) applying the GINA analysis software (Elysia-Raytest; Angleur, Belgium). Radio-HPLC was conducted on an Infinity 1200 analytical HPLC system from Agilent Technologies (Waldbronn, Germany), coupled to a Ramona * radiodetector from Elysia-Raytest (Angleur, Belgium). The VDSpher PUR 150 C18-E column (5 µm, 100 × 40 m) was eluted applying a linear gradient of 5–45% MeCN (+0.1% TFA)/95–55% H<sub>2</sub>O (+0.1% TFA) in 10 min (system 2). No indices for tracer instability were detected in the period between synthesis and image acquisition.

### 4.2. Cell Studies

#### 4.2.1. Cell Culture

The HEK293 cell line transfected to stably express the human SST<sub>2</sub>R, tagged with the T7-epitope (HEK293-SST<sub>2</sub>R), was offered by S. Schultz (Jena, Germany) [33]. Wild type HEK293 cells, devoid of SST<sub>2</sub>R expression, served as negative controls (wtHEK293). Cells were cultured in controlled humidified air with 5% CO<sub>2</sub> at 37°C in Dulbecco’s Modified Eagle Medium (DMEM), containing Glutamax-I and supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL streptomycin and 400 µg/mL G418; the latter was not added during culturing of wtHEK293 cells. All culture media were provided by Gibco BRL, Life Technologies (Grand Island, NY, USA) and
supplements were supplied by Biochrom KG Seromed (Berlin, Germany). Sub-culturing was achieved by treating the cells with a trypsin/EDTA (0.05%/0.02% w/v) solution.

4.2.2. Competition Binding Assays in HEK293-SST₂R Cell Membranes

Competition binding assays for DATA₅m-LM4 and [¹¹⁷⁷Ga]Ga-DATA₅m-LM4 were performed in freshly harvested HEK293-SST₂R cell membranes against [¹²⁵I-Tyr²⁵]TIT-SS₂₈ [30,33]. In short, to each triplicate of assay tube corresponding to a different concentration point, the following were added: i. the test compound or the reference (30 µL solution of increasing concentrations, 10⁻⁵–10⁻¹³ M), ii. the radioligand (70 µL, 50 pM corresponding to ≈ 40,000 cpm) and iii. the membrane homogenate (200 µL) to a final volume of 300 µL in binding buffer (50 mM HEPES pH 7.4, 1% BSA, 5.5 mM MgCl₂, 35 µM bacitracin). Samples were incubated for 1 h at 22 °C in an Incubator Orbital Shaker unit, (MPM Instr. Srl) and a chilled washing buffer (10 mM HEPES pH 7.4, 150 mM NaCl) was added to stop the reaction. Samples underwent rapid filtration through glass fiber filters (Whatman GF/B, pre-soaked for 2 h in a 1 % polyethyleneimine (PEI) aqueous solution) on a Brandel Cell Harvester (Adi Hassel Ingenieur Büro, Munich, Germany) and were washed with ice-cold washing buffer (10 mM HEPES pH 7.4, 150 mM NaCl). Filters were collected and their activity measured in a γ-counter (automated multi-sample well-type instrument with a NaI(Tl) 3" crystal, Canberra Packard Cobra™ Quantum U5003/1, Auto-Gamma® counting system). The half-maximal inhibitory concentration (IC₅₀) values were calculated by nonlinear regression for a one-site model applying the PRISM™ 6.0 GraphPad software (San Diego, CA, USA) and represent mean IC₅₀ ± sd values from at least three independent experiments were performed in triplicate.

4.2.3. Radioligand Uptake/Internalization in HEK293-SST₂R Cells

The uptake/internalization of [⁶⁷Ga]Ga-DOTA-TOC, [⁶⁷Ga]Ga-DOTA-LM3 and [⁶⁷Ga]Ga-DATA₅m-LM4 were compared by 1 h incubation in HEK293-SST₂R cells at 37 °C. Cells were seeded in poly-lysine coated six-well plates (1 × 10⁶/well) and grew to confluent monolayers overnight. At the day of the experiment, plates were placed on ice and rinsed twice with chilled internalization medium (DMEM Glutamax-I supplemented by 1% (v/v) FBS). Fresh medium was added (1.2 mL) at room temperature, followed by a solution of [⁶⁷Ga]Ga-DOTA-TOC, [⁶⁷Ga]Ga-DOTA-LM3 or [⁶⁷Ga]Ga-DATA₅m-LM4 (50,000 cpm corresponding to 0.5 pmol total peptide in 150 µL 0.5% BSA PBS). In the upper three wells internalization medium was added (150 µL, total) and in the lower three a solution of TATE to a final concentration of 1 µM (150 µL, non-specific). After 60 min incubation at 37 °C, the medium was removed and cells were washed with ice-cold 0.5% BSA-PBS. Cells were incubated (2 × 5 min) at ambient temperature in acid wash buffer (50 mM glycine in 0.1 M NaCl, pH 2.8) and supernatants were collected (membrane-bound fraction). After rinsing with 0.5% BSA-PBS, the cells were lysed by treatment with 1 N NaOH; the lysates were collected (internalized fraction). Samples were measured in the γ-counter and cell-associated/internalized radioactivity vs. total added activity per well was calculated. Specific values were obtained by subtracting values in the presence of excess TATE (lower well triplicates) from those without the addition of blocker (upper well triplicates). Results represent average ± sd values from at least three independent experiments.

4.3. Animal Studies

4.3.1. Stability Studies

The metabolic stability of [⁶⁷Ga]Ga-DATA₅m-LM4 was assessed in three healthy male Swiss albino mice provided by the NCSR “Demokritos” Animal House (Athens, Greece; body weight: 30 ± 5 g). Mice were injected through their tail vein with a 100-µL bolus containing the radioligand (up to 11 MBq corresponding to 2.5–3 nmol of total conjugate in vehicle: saline/EtOH 9/1 v/v) and were euthanized 5 min post-injection (pi). Blood was directly withdrawn from the heart in a pre-chilled syringe and placed in an ice-cold Eppendorf Protein LoBind® tube on ice containing EDTA (40 µL, 50 mM Na₂EDTA
solution). Samples were centrifuged (10 min, 2000 × g/4 ◦C, in a Hettich Universal 320R centrifuge, Tuttlingen, Germany), the plasma was collected and cold MeCN was added in a 1/1 v/v ratio. Samples were centrifuged once more (10 min, 15,000 × g/4 ◦C) and supernatants were concentrated to a small volume (∼50–100 µL) under a gentle N2-flux at 40 ◦C. Physiological saline (400 µL) was added and the solution was passed through a Millex GV filter (0.22 µm, 13 mm Ø, Millipore, Milford, MI, USA). Filtrate samples were analyzed by HPLC (system 1) [34]. The elution time (tR) of intact [67Ga]Ga-DATA5m-LM4 was determined by co-injection of blood samples with an aliquot of the labeling solution. Results as average percentage of intact radioligand ± sd were acquired from three mice.

4.3.2. Biodistribution in SCID Mice Bearing Twin HEK293-SST2R and wtHEK293 Tumors

Inocula containing a suspension of freshly-harvested HEK293-SST2R cells (150 µL, 1.2 × 10⁷ cells in normal saline) and wtHEK293 cells (150 µL, 0.6 × 10⁷ cells in normal saline) were subcutaneously (sc) injected in the right and left flanks of male SCID mice (21.5–25.0 g body weight, six weeks of age on arrival day; NCSR “Demokritos” Animal House, Athens, Greece). Mice were kept under aseptic conditions for about 2 weeks until well-palpable tumors (300–600 mg) were grown at the inoculation sites [28]. On the day of biodistribution, animals received a 100 µL-bolus through the tail vein containing [67Ga]Ga-DOTA-LM3 or [67Ga]Ga-DATA5m-LM4 (37 kBq, 10 pmol total peptide) and were euthanized in groups of four at 1 and 4 h pi. Samples of blood and tissues of interest were collected along with implanted tumors, weighted and counted in the gamma counter. Biodistribution results were calculated as percent of the injected activity per gram tissue (%IA/g) with the aid of appropriate standards of the administered dose and the Microsoft Excel program. Results are presented as mean %IA/g values ± sd, n = 4 per time point, as determined by the PRISM™ 6.0 GraphPad software (San Diego, CA, USA).

Mice experiments complied with European and national regulations in licensed facilities (EL 25 BIO exp021). The study protocols were approved by the Department of Agriculture and Veterinary Service of the Prefecture of Athens (#1609, 24-04-2019 for the stability studies and #1610, 24-04-2019 for the biodistribution and imaging studies).

4.3.3. Statistical Analysis

For statistical comparison of the results, a two-way ANOVA with multiple comparisons and Tukey’s post-hoc analysis was applied (PRISM™ 6.0 GraphPad Software, San Diego, CA, USA). p values of < 0.05 were considered to be statistically significant.

4.4. Patient Study

The patient signed written informed consent before the study. He was intravenously injected with a dose of [68Ga]Ga-DATA5m-LM4 adopted to his body weight (1.8–2.2 MBq/kg). PET/CT images were acquired 1 h pi from the vertex to the proximal femora on a Biograph Vision 600 Edge PET/CT scanner (Siemens Healthineers AG; Erlangen, Germany). A low-dose CT scan from head to the proximate thigh was obtained for attenuation correction and anatomical mapping. Next, whole-body PET was performed with 2 min per bed position (5–7 bed positions depending on the height of the patient). The patient had a good renal function and showed no allergies to any of the ingredients of the radiopharmaceuticals. PET/CT images were anonymized and reviewed by two experienced nuclear medicine experts who were not blinded to patient medical history on the reconstructed images.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms232314590/s1.

Author Contributions: Conceptualization, B.A.N., F.R. and T.M.; methodology, B.A.N., R.P.B., F.R. and T.M.; validation, B.A.N., R.P.B., F.R. and T.M.; formal analysis, P.K., L.G. and T.M.; investigation, P.K., B.A.N., L.G. and T.M.; resources, P.K., R.P.B., F.R. and T.M.; data curation, P.K., B.A.N., L.G. and T.M.; writing—original draft preparation, T.M.; writing—review and editing, all authors; visualization, P.K., B.A.N., L.G. and T.M.; supervision, F.R., R.P.B. and T.M.; project administration, F.R.,
R.P.B. and T.M.; funding acquisition, F.R. and T.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded via a grant by International Centers for Precision Oncology (ICPO) Foundation, Wiesbaden, Germany, grant: “New SST2 R-antagonists in the diagnosis of neuroendocrine tumors with PET/CT”.

**Institutional Review Board Statement:** The animal study protocols were approved by the Department of Agriculture and Veterinary Service of the Prefecture of Athens (#1609, 24-04-2019: for stability studies, #1610, 24-04-2019: for biodistribution and imaging studies). The patient study did not require ethical approval due to its retrospective nature. Additionally, all imaging procedures were part of routine follow-up examinations. This study was conducted in accordance with the Declaration of Helsinki. 198GaGa-DATA®.LM4 was administered in compliance with The German Medicinal Products Act (AMG § 13 2b) and in accordance with the responsible regulatory body.

**Informed Consent Statement:** Informed consent was obtained from the patient in the study.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** We thank the medical personnel involved in scanning and data acquisition as well as the patient who underwent the imaging procedure.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Reubi, J.C. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. *Neuroendocrinology* 2004, 80 (Suppl. 1), 51–56. [CrossRef] [PubMed]
2. van Essen, M.; Sundin, A.; Krenning, E.P.; Kwekkeboom, D.J. Neuroendocrine tumours: The role of imaging for diagnosis and therapy. *Nat. Rev. Endocrinol.* 2014, 10, 102–114. [CrossRef] [PubMed]
3. Levine, R.; Krenning, E.P. Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: Historical review based on an interview of Eric P. Krenning by Rachel Levine. *J. Nucl. Med.* 2017, 58 (Suppl. 2), 35–95. [CrossRef] [PubMed]
4. Baum, R.P.; Kulkarni, H.R.; Carreras, C. Peptides and receptors in image-guided therapy: Theranostics for neuroendocrine neoplasms. *Semin. Nucl. Med.* 2012, 42, 190–207. [CrossRef] [PubMed]
5. Baum, R.P.; Kulkarni, H.R. Theranostics: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-the Bad Berka experience. *Theranostics* 2012, 2, 437–447. [CrossRef]
6. Decristoforo, C.; Maina, T.; Nock, B.; Gabriel, M.; Cordopatis, P.; Moncayo, R. 99mTc-Demotate 1: First data in tumour patients-results of a pilot/phase I study. *Eur. J. Nucl. Med. Mol. Imaging* 2003, 30, 1211–1219. [CrossRef]
7. de Jong, M.; Breeman, W.A.; Bakker, W.H.; Kooij, P.P.; Bernard, B.F.; Hofland, L.J.; Visser, T.J.; Srinivasan, A.; Schmidt, M.A.; Erion, J.L.; et al. Comparison of 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. *Cancer Res.* 1998, 58, 437–441.
8. de Jong, M.; Breeman, W.A.; Kwekkeboom, D.J.; Valkema, R.; Krenning, E.P. Tumor imaging and therapy using radiolabeled somatostatin analogs. *Acc. Chem. Res.* 2009, 42, 873–880. [CrossRef]
9. Anderson, C.J.; Ferdani, R. Copper-64 radiopharmaceuticals for PET imaging of cancer: Advances in preclinical and clinical research. *Cancer Biol. Ther.* 2009, 24, 379–393. [CrossRef]
10. Kwekkeboom, D.J.; de Herder, W.W.; Kam, B.L.; van Eijck, C.H.; van Essen, M.; Kooij, P.P.; Feelders, R.A.; van Aken, M.O.; Krenning, E.P. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: Toxicity, efficacy, and survival. *J. Clin. Oncol.* 2008, 26, 2124–2130. [CrossRef]
11. Zhang, J.; Kulkarni, H.R.; Baum, R.P. 225Ac-DOTATOC-targeted somatostatin receptor alpha-therapy in a patient with metastatic neuroendocrine tumor of the thymus, refractory to beta-radiation. *Clin. Nucl. Med.* 2021, 46, 1030–1031. [CrossRef] [PubMed]
12. Delpassand, E.S.; Tworowska, I.; Esfandiari, R.; Torgue, J.; Hurt, J.; Shafie, A.; Nunez, R. Targeted alpha-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic sstr-expressing neuroendocrine tumors: First-in-humans dose-escalation clinical trial. *J. Nucl. Med.* 2022, 63, 1326–1333. [CrossRef] [PubMed]
13. Henrich, U.; Kopka, K. LuTathera®: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. *Pharmaceuticals* 2019, 12, 114. [CrossRef] [PubMed]
14. Ginja, M.; Zhang, H.; Waser, B.; Cescato, R.; Wild, D.; Wang, X.; Erchegyi, J.; Rivier, J.; Macke, H.R.; Reubi, J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. *Proc. Natl. Acad. Sci. USA* 2006, 103, 16436–16441. [CrossRef] [PubMed]
15. Cescato, R.; Erchegyi, J.; Waser, B.; Piccard, V.; Maecke, H.R.; Rivier, J.E.; Reubi, J.C. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. *J. Med. Chem.* 2008, 51, 4030–4037. [CrossRef] [PubMed]
16. Fani, M.; Nicolás, G.P.; Wild, D. Somatostatin receptor antagonists for imaging and therapy. J. Nucl. Med. 2017, 58 (Suppl. 2), 615–668. [CrossRef]

17. Wild, D.; Fani, M.; Béhé, M.; Brink, I.; Rivier, J.E.; Reubi, J.C.; Maecke, H.R.; Weber, W.A. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J. Nucl. Med. 2011, 52, 1412–1417. [CrossRef]

18. Wild, D.; Fani, M.; Fischer, R.; Del Pozzo, L.; Kaul, F.; Krebs, S.; Fischer, R.; Rivier, J.E.; Reubi, J.C.; Maecke, H.R.; et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: A pilot study. J. Nucl. Med. 2014, 55, 1248–1252. [CrossRef]

19. Nicol

20. Cescato, R.; Waser, B.; Fani, M.; Reubi, J.C. Evaluation of $^{177}$ Lu-DOTA-sst2 antagonist versus $^{177}$ Lu-DOTA-sst2 agonist binding in human cancers in vitro. J. Nucl. Med. 2011, 52, 1886–1890. [CrossRef]

21. Mansi, R.; Fani, M. Design and development of the theranostic pair $^{177}$ Lu-OPS201/$^{68}$ Ga-OPS202 for targeting somatostatin receptor expressing tumors. J. Labelled Comp. Radiopharm. 2019, 62, 635–645. [CrossRef] [PubMed]

22. Fani, M.; Braun, F.; Waser, B.; Beetschen, K.; Cescato, R.; Erchegyi, J.; Rivier, J.E.; Weber, W.A.; Maecke, H.R.; Reubi, J.C. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J. Nucl. Med. 2012, 53, 1481–1489. [CrossRef] [PubMed]

23. Breeman, W.A.; de Blois, E.; Sze Chan, H.; Konijnenberg, M.; Kweekkeboom, D.J.; Krenning, E.P. $^{68}$ Ga-labeled DOTA-peptides and $^{68}$ Ga-labeled radiopharmaceuticals for positron emission tomography: Current status of research, clinical applications, and future perspectives. Semin. Nucl. Med. 2011, 41, 314–321. [CrossRef] [PubMed]

24. Mueller, D.; Breeman, W.A.; Klette, I.; Gottschaldt, M.; Odparlik, A.; Baehre, M.; Tworowska, I.; Schultz, M.K. Radiolabeling of DOTA-like conjugated peptides with generator-produced $^{68}$ Ga and using NaCl-based cationic elution method. Nat. Protoc. 2016, 11, 1057–1066. [CrossRef]

25. Seemann, J.; Waldron, B.P.; Roesch, F.; Parker, D. Approaching ‘kit-type’ labelling with $^{68}$ Ga: The DATA chelators. ChemMedChem 2015, 10, 1019–1026. [CrossRef]

26. Spang, P.; Herrmann, C.; Roesch, F. Bifunctional gallium-68 chelators: Past, present, and future. Semin. Nucl. Med. 2016, 46, 373–394. [CrossRef]

27. Seemann, J.; Waldron, B.; Parker, D.; Roesch, F. DATATOC: A novel conjugate for kit-type $^{68}$ Ga labelling of TOC at ambient temperature. EJNMNI Radiopharm. Chem. 2017, 1, 4. [CrossRef]

28. Nock, B.A.; Kaloudi, A.; Nagel, J.; Sinnes, J.P.; Roesch, F.; Maina, T. Novel bifunctional data chelator for quick access to site-directed PET Ga-68-radiotracers: Preclinical proof-of-principle with [Tyr$^3$]octreotide. Dalton Trans. 2017, 46, 14584–14590. [CrossRef]

29. Yadav, D.; Ballal, S.; Yadav, M.P.; Tripathi, M.; Roesch, F.; Bal, C. Evaluation of $^{68}$ Ga-Ga-DATA-TOC for imaging of neuroendocrine tumours: Comparison with $^{68}$ Ga-Ga-DATA-NOC PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 860–869. [CrossRef]

30. Sinnes, J.P.; Nagel, J.; Waldron, B.P.; Maina, T.; Nock, B.A.; Bergmann, R.K.; Ullrich, M.; Pietzsch, J.; Bachmann, M.; Baum, R.P.; et al. Instant kit preparation of $^{68}$ Ga-radiopharmaceuticals via the hybrid chelator DATA: Clinical translation of $^{68}$ Ga-Ga-DATA-TOC. EJNNMI Res. 2019, 9, 48. [CrossRef]

31. Seemann, J.; Waldron, B.; Parker, D.; Roesch, F. DATATOC: A novel conjugate for kit-type $^{68}$ Ga labelling of TOC at ambient temperature. EJNMNI Radiopharm. Chem. 2017, 1, 4. [CrossRef]

32. Baumann, R.P.; Zhang, J.; Schuchardt, C.; Müller, D.; Macke, H. First-in-humans study of the SSTR antagonist $^{177}$ Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: Dosimetry, safety, and efficacy. J. Nucl. Med. 2021, 62, 1571–1581. [CrossRef] [PubMed]

33. Mroz, P.A.; Perez-Tilve, D.; Liu, F.; Gelfanov, V.; DiMarchi, R.D.; Mayer, J.P. Pyridyl-alanine as a hydrophilic, aromatic element in peptide structural optimization. J. Med. Chem. 2016, 59, 8061–8067. [CrossRef] [PubMed]

34. Nock, B.A.; Maina, T.; Krenning, E.P.; de Jong, M. “To serve and protect”: Enzyme inhibitors as radiopeptide escorts promote tumor targeting. J. Nucl. Med. 2014, 55, 121–127. [CrossRef] [PubMed]